Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707

Reuters

2025/05/20

Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707

Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250519321225) on May 20, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"澳洲华人首选美澳港股一站式交易平台 | 老虎证券","description":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","keywords":"老虎证券,老虎证券澳洲,老虎证券股票,老虎证券开户,老虎证券app,tigertrade老虎证券,股票,asx美股,炒股,券商,澳洲股票交易,澳大利亚炒股","social":{"ogDescription":"澳、美、港、A股、ETF、期权一站式在线交易，超低佣金，新手也能轻松开启投资。在老虎证券， 1 美元起投资美股，24/5 无时差交易美股，澳大利亚华人信赖的在线炒股平台。","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2536656426"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536656426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536656426?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-20 08:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536656426","market":"us","top_or_hot":-1,"title":"Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250519321225) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-05-20 08:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250519321225) on May 20, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250520:nNDL666Bj5:1","article_id":"2536656426","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536656426","pubTimestamp":1747699219,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","01530":"三生制药","BK1161":"生物科技","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4581":"高盛持仓","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4599":"减肥药","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","LU0234572021.USD":"高盛美国核心股票组合Acc","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0122379950.USD":"贝莱德世界健康科学A2","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","LU0058720904.USD":"联博国际健康护理基金A","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4533":"AQR资本管理(全球第二大对冲基金)","BK1583":"高瓴概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","BK4592":"伊斯兰概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","SG9999002232.USD":"Allianz Global High Payout USD","BK4588":"碎股","PFE":"辉瑞","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF"},"translate_title":"辉瑞公司宣布与三生制药达成独家许可协议，开发有前途的抗癌药物SSGJ-707","themeId":"bd3435deb4a10905f161714b2e190399","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"01530":0.9},"content_text":"Pfizer Inc. Announces Exclusive Licensing Agreement with 3SBio for Development of Promising Cancer Drug SSGJ-707\n    \n\n        Pfizer Inc. has announced an exclusive global licensing agreement with 3SBio, Inc., a prominent Chinese biopharmaceutical company, for the development, manufacturing, and commercialization of SSGJ-707. This bispecific antibody targets PD-1 and VEGF and is currently involved in clinical trials in China for various cancers, including non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. Under the agreement, Pfizer will gain an exclusive global license, excluding China, and will make a $100 million equity investment in 3SBio upon closing, subject to customary conditions and approvals. Additionally, 3SBio will receive an upfront payment of $1.25 billion and may receive up to $4.8 billion in milestone payments. Tiered double-digit royalties on sales of SSGJ-707, if approved, are also part of the agreement. Pfizer plans to produce the drug substance in Sanford, North Carolina, and the drug product in McPherson, Kansas.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250519321225) on May 20, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}